About this trial
Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years and older
Diagnosed with heart failure at the time of discharge
Have an ejection fraction (based on imaging modalities such as echocardiography or cardiac MRI) recorded closest to the time of discharge, showing a left ventricular ejection fraction of less than 50%
Disqualifiers
Patients and their relatives do not have means of communication with healthcare staff (phone, computer, messaging, etc.)
Patients do not reside in Vietnam after discharge
Trial population
All eligible patients discharged with a diagnosis of heart failure with reduced or mildly reduced ejection fraction.
Trial design
Case-control
Prospective
Treatments tested in this trial
Optimal treatment
DrugOptimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
Treatment groups
Trial outcomes
Primary outcomes
All-cause mortality
Death from any cause
Heart failure rehospitalization
Patient rehospitalization due to cardiovascular causes, excluding apparent non-cardiac causes.
Secondary outcomes
Major adverse cardiovascular events
Acute myocardial infarction, stroke or death from any cause
Guideline-directed medical therapy detail
Information regarding guideline-directed medical therapy, including medications used and dose titration over time.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.